Primate Diseases

Diseases of animals within the order PRIMATES. This term includes diseases of Haplorhini and Strepsirhini.

Also Known As:

Disease, Primate; Diseases, Primate; Primate Disease

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Disease Context: Research Results

Animal Diseases: 416
- Primate Diseases: 5

Experts

1.	Yan, Victoria C: 1 article (04/2022)
2.	Ai, Xingbin: 1 article (01/2019)
3.	Aman, M Javad: 1 article (01/2019)
4.	Aven, Linh: 1 article (01/2019)
5.	Barrios, Juliana: 1 article (01/2019)
6.	Didier, Peter J: 1 article (01/2019)
7.	Doyle-Meyers, Lara: 1 article (01/2019)
8.	Ennis, Jane: 1 article (01/2019)
9.	Holtsberg, Rick: 1 article (01/2019)
10.	Karauzum, Hatice: 1 article (01/2019)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Primate Diseases:

1.	ProdrugsIBA 04/14/2022 - "This work highlights the pharmacodynamic discordance of remdesivir between humans and non-human primates, thereby demonstrating that non-human primate disease models overestimate the therapeutic efficacy of phosphoramidate prodrugs."
2.	phosphoramidic acidIBA 04/14/2022 - "This work highlights the pharmacodynamic discordance of remdesivir between humans and non-human primates, thereby demonstrating that non-human primate disease models overestimate the therapeutic efficacy of phosphoramidate prodrugs."
3.	remdesivirIBA 04/14/2022 - "This work highlights the pharmacodynamic discordance of remdesivir between humans and non-human primates, thereby demonstrating that non-human primate disease models overestimate the therapeutic efficacy of phosphoramidate prodrugs."
4.	gamma-Aminobutyric Acid (GABA)IBA 01/01/2019 - "In this study, we characterized the cellular source of GABA in the lungs of nonhuman primates and humans and assessed GABA secretion and signaling in primate disease models. "
5.	Investigational DrugsIBA 01/01/2019 - "These results represent the successful therapeutic in vivo protection by two investigational drugs against SEB in a severe nonhuman primate disease model and punctuate the therapeutic value of monoclonal antibodies when faced with treatment options for SEB-induced toxicity in a postexposure setting."
6.	VaccinesIBA 02/08/2017 - "Within a short time period, useful mouse and non-human primate disease models have been established, and pre-clinical evaluation of therapeutics and vaccines has begun. "
7.	Antiviral Agents (Antivirals)IBA 04/17/2014 - "Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. "
8.	Monoclonal AntibodiesIBA 01/01/2019 - "These results represent the successful therapeutic in vivo protection by two investigational drugs against SEB in a severe nonhuman primate disease model and punctuate the therapeutic value of monoclonal antibodies when faced with treatment options for SEB-induced toxicity in a postexposure setting."

Therapies and Procedures

1.	Therapeutics 02/08/2017 - "Within a short time period, useful mouse and non-human primate disease models have been established, and pre-clinical evaluation of therapeutics and vaccines has begun. " 04/17/2014 - "Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. "